Equities

CoDon AG

CoDon AG

Actions
  • Price (EUR)0.0185
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-20.26%
  • Beta--
Data delayed at least 15 minutes, as of May 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Co.don AG is a Germany-based company that is active in the tissue engineering and regenerative medicine industry. The Company manufactures cell-based biological drugs for the use in orthopedic and neurosurgical applications. Its products are used for the treatment of focal particular cartilage defects, lumbar disc herniation, non-union fractures and dental disorders. Those include co don chondrotransplant, which is used for cartilage treatment, particularly in the knee area; co don chondrosphere, which is a three-dimensional articular cartilage cultivated outside of the body; co don chondrotransplant DISC, for the regeneration of intervertebral discs, and co don osteotransplant DENT, which is an autologous bone cell transplant for dental applications. The Company is active domestically and in other European countries.

  • Revenue in EUR (TTM)9.84m
  • Net income in EUR-14.13m
  • Incorporated1999
  • Employees134.00
  • Location
    CoDon AGWarthestrasse 21TELTOW 14513GermanyDEU
  • Phone+49 332843460
  • Fax+49 3 328434643
  • Websitehttps://www.codon.de/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.